The TRS‐HFDM discriminates for HF specific risk among people with T2DM. Using the TRS‐HFDM to identify those who maximally benefit from therapies that reduce HF risk warrants evaluation (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: ACCORD
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention (Diabetes Care)
Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial
The increased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely to be explained by QT prolongation leading to lethal ventricular arrhythmias (Diabetes)
Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial
The increased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely to be explained by QT prolongation leading to lethal ventricular arrhythmias (Diabetes)
Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial
Long-term visit-to-visit HbA1c variability was a strong predictor of all-cause mortality. HbA1c VIM combined with HbA1c mean conferred an increased risk for all-cause mortality in the intensive-therapy group (Diabetes Care)
Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study
TZD use was associated with increased non-spine fractures in women, but not men, with type 2 diabetes. When women discontinued TZD use, the fracture effects were attenuated (Journal of Clinical Endocrinology & Metabolism)
Glycosmedia is also available as an App: